Federal Judge Allows Eli Lilly Lawsuit Against Compounded Tirzepatide Seller to Proceed
核心洞察
A federal judge ruled that Eli Lilly can proceed with its lawsuit against Mochi Health Corp. (搜索), a telehealth company selling compounded versions of tirzepatide drugs Zepbound and Mounjaro.
The court found that Lilly successfully demonstrated economic harm through diverted sales and reputational damage from consumer confusion between compounded and FDA-approved medications.
Studies cited in the case indicate higher adverse side effects among users of compounded GLP-1 (搜索) inhibitors compared to FDA-approved formulations.
A federal judge has ruled that Eli Lilly & Co. can proceed with its unfair competition lawsuit against Mochi Health Corp. (搜索), a telehealth company selling compounded versions of the pharmaceutical giant's tirzepatide drugs Zepbound and Mounjaro. U.S. District Judge Jacqueline Scott Corley for the Northern District of California allowed the case to advance after Lilly filed an amended complaint addressing previous deficiencies.
Court Finds Sufficient Evidence of Harm
Judge Corley determined that Lilly successfully demonstrated how Mochi Health's actions harm both the drugmaker's business and consumer perception of FDA-approved tirzepatide. "As to economic injury, Lilly alleges Mochi Health diverts potential customers — and concomitant sales — from Lilly's FDA-approved medications through its corporate practice of medicine as well as a series of misleading advertisements," Corley stated in Monday's order.
The ruling represents a significant development in Lilly's second attempt to pursue the case, after the judge previously dismissed the lawsuit for failing to articulate specific harms. The amended complaint successfully addressed these concerns, allowing claims under California's Unfair Competition Law and the federal trademark Lanham Act to proceed.
Corporate Practice of Medicine Violations Alleged
Central to Lilly's case are allegations that Mochi Health violates California's prohibition on corporate practice of medicine, where business entities without medical licenses make medical decisions motivated by profit rather than patient care. According to the complaint, Mochi Health hires physicians working at its entities, advertises for them, and provides "diagnostic protocols" related to obesity (搜索) medicine.
The California Medical Association (搜索) filed an amicus brief supporting Lilly's position, emphasizing the importance of the state's prohibition on lay entities employing doctors or dictating medical care. "Lilly's complaint includes many allegations that, if proven, depict both classic and more nuanced violations of [corporate practice of medicine]," the organization argued.
Safety and Quality Concerns Highlighted
The court noted Lilly's argument that studies indicate a higher incidence of adverse side effects among users of compounded GLP-1 (搜索) inhibitors, such as tirzepatide, compared to FDA-approved formulations. The ruling also referenced findings showing consumer confusion about differences between compounded medications and FDA-approved drugs.
These safety concerns gained additional weight following regulatory action against Aequita Pharmacy (搜索), the compounder that owns Mochi Health and produces its tirzepatide drugs. Washington's Pharmacy Quality Assurance Commission stopped production at the facility last year because it allowed untrained and unqualified staff to perform sterile compounding and failed to properly supervise staff.
Broader Industry Implications
The ruling addresses growing tensions between major pharmaceutical companies and telehealth businesses that have made significant inroads into the weight loss drug market. These companies sell compounded versions of popular medications that don't require FDA approval and, according to large drugmakers, aren't as rigorously tested for safety, efficacy, and quality.
Lilly has pursued similar legal action against three other telehealth sellers of compounded tirzepatide drugs, obtaining more than a dozen permanent injunctions against various telehealth companies, medspas, and mass compounders.
Mixed Ruling with Opportunity for Amendment
While allowing most claims to proceed, Judge Corley granted Mochi Health's request to dismiss Lilly's civil conspiracy claim, stating the amended complaint "does not include allegations supporting a plausible inference of an agreement to a common plan among Mochi Health, the Mochi Medical defendants, and Aequita Pharmacy (搜索)." She provided Lilly another opportunity to amend the lawsuit to address these shortcomings.
A Lilly representative responded to the ruling by stating: "The court's decision confirms that common tactics used by many mass compounders are false and misleading, including advertising compounded knockoffs as FDA-approved or clinically proven and marketing standardized, mass compounded tirzepatide drugs as 'personalized' for patients."
Mochi Health expressed satisfaction with aspects of the ruling, with a spokesperson stating: "We remain confident in our position and look forward to demonstrating through the discovery process that Mochi operates lawfully and in the best interest of patients."